Use access key #2 to skip to page content.
$39.02 -3.29 (-7.78%)
12/1/2008 4:00 PM

Biogen Idec, Inc. (BIIB)

CAPS Rating:
****

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

View All Commentary (BIIB)

Recs

0

Avatar TMFBreakerJava (95.05) Submitted: 3/06/08 10:52 AM : Outperform Start Price: $59.28 BIIB Score: 3.81

They have taken themselves off the market and the price has pulled back. Tysabri sales continue to ramp and a number of price moving events are coming up this year. I expect that the price will be meaningfully higher by the end of the year.

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links